In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Takeda pays $5.2bn for Iclusig developer Ariad Pharmaceuticals

Executive Summary

Takeda Pharmaceutical Co. Ltd., via a newly created entity called Kiku Merger Co. Inc., acquired publicly traded Ariad Pharmaceuticals Inc. (oncology therapeutics) for $5.2bn, paying $24 in cash per share (an 89% premium).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Contract
    • Payment Includes Cash
    • Full Acquisition

Related Companies

Advertisement
UsernamePublicRestriction

Register